Paclitaxel and cisplatin treatment of recurrent metastatic Breast Cancer.docVIP

 PAGE \* MERGEFORMAT 7 Paclitaxel and cisplatin treatment of recurrent metastatic Breast Cancer [Abstract] Objective To observe the PC paclitaxel and cisplatin in the treatment of recurrent and metastatic breast cancer, the efficacy and toxicity. Methods paclitaxel 135mg / (m2 * d) intravenous infusion, day 1, the first 15 days, cisplatin (Nuoxin) 20mg / (m2 * d) intravenous infusion, 1 to 4 days. The group of 24 patients with recurrent and metastatic breast cancer, 28 days a cycle, used in conjunction two cycles were evaluated. Results All 24 patients were evaluated both, CR 2 Li (8.3%), PR 11 cases (45.8%), overall response rate (CR PR) was 54.2% (13/24). The main side effects of decreased white blood cell count accounted for 100.0%, of which for the three cases of grade Ⅱ (12.5%), Ⅲ degree of 12 cases (50.0%), Ⅳ degree of 9 cases (37  5%), Ⅲ ~ Ⅳ degree accounted for 87.5%; Ⅱ degree of platelet decline in eight cases (33.3%), Ⅲ ~ Ⅳ degree 1 case (4.2%); anemia in two cases of grade Ⅲ (8.3%); the incidence of nausea and vomiting in 11 cases (45.8%), Ⅲ degree does not appear. Conclusion paclitaxel and cisplatin treatment of recurrent metastatic breast cancer a higher bone marrow toxicity than the obvious response to mild gastrointestinal tract. [Keywords:] recurrent and metastatic breast cancer; paclitaxel; cis-platinum; anti-cancer chemotherapy Study of the efficacy on paclitaxel plus cisplatin combined therapy in the treatment of metastatic breast cancer [Abstract] Objective To evaluate the results of combined chemotherapy with paclitaxel (PTX) plus cisplatin (DDP) in the treatment of metastatic breast cancer.Methods 24 patiets with metastatic breast cancer PTX 135mg / m2 by intravenous infusion on day1, 15, and DDP 20mg/m2 by intravenous infusion on day 1 ~ 4  The treatment was repeated every 28 day, up to 2 cycles.Results 24 patients were evaluable for efficacy. The response rate (RR) was 54.2% (CR: 2, PR: 11 ). The major toxicitie